Pinocembrin 7-O-[3-O-galloyl-4,6-hexahydroxydiphenoyl]-beta-D-glucoside is a TRPV1 antagonist and HDAC7 inhibitor. Pinocembrin 7-O-[3-O-galloyl-4,6-hexahydroxydiphenoyl]-beta-D-glucoside blocks TRPV1-mediated calcium influx, suppresses phosphorylation of p65, IkappaBalpha, p38, JNK, and ERK1/2, inhibiting NF-kappaB and MAPK signaling cascades. Pinocembrin 7-O-[3-O-galloyl-4,6-hexahydroxydiphenoyl]-beta-D-glucoside reduces production and gene expression of pro-inflammatory cytokines IL-1beta, IL-6, and TNF-alpha. Pinocembrin 7-O-[3-O-galloyl-4,6-hexahydroxydiphenoyl]-beta-D-glucoside exhibits potent analgesic activity, elevates thermal pain threshold and mechanical pain threshold in murine models. Pinocembrin 7-O-[3-O-galloyl-4,6-hexahydroxydiphenoyl]-beta-D-glucoside restores CD8+ T cell infiltration into bladder cancer tumors and improves bladder cancer immunotherapy efficacy. Pinocembrin 7-O-[3-O-galloyl-4,6-hexahydroxydiphenoyl]-beta-D-glucoside can be used for the researches of painand bladder cancer[1][2].
